Intestinal Cell News

Intestinal Cell News is an online resource that curates the latest research using intestinal cells.

JAK/STAT3 Represents a Therapeutic Target for Colorectal Cancer Patients with Stromal-Rich Tumors

[Journal Of Experimental & Clinical Cancer Research] Scientists investigated the use of JAK inhibitors for anti-cancer activity in coloretal cancer cell lines, mouse model organoids and patient-derived organoids.

Identifying Regulators of Aberrant Stem Cell and Differentiation Activity in Colorectal Cancer Using a Dual Endogenous Reporter System

[Nature Communications] Researchers engineered a dual endogenous reporter system by genome-editing the SOX9 and KRT20 loci of human colorectal cancer cell lines to express fluorescent reporters, broadcasting aberrant stem cell-like and differentiation activity, respectively.

Johnson & Johnson Submits Supplemental Biologics License Application to U.S. FDA Seeking Approval of TREMFYA®(guselkumab) for the Treatment of Adults with Moderately to Severely...

[Johnson & Johnson] Johnson & Johnson announced the submission of a supplemental Biologics License Application to the US FDA seeking approval of TREMFYA® for treatment of adults with moderately to severely active ulcerative colitis.

Researchers Awarded £2.6M to Develop Preclinical Lead Drug Candidate for Advanced Prostate and Colorectal Cancers

[University of Strathclyde] Researchers at the University of Strathclyde have been awarded £2.6 million to develop a preclinical lead drug candidate targeted at advanced prostate and colorectal cancers.

SLC26A9 Promotes Colorectal Tumorigenesis by Modulating Wnt/β-Catenin Signaling

[Cell Death Discovery] Researchers explored the role of solute carrier family 26 member 9 (SLC26A9) in colorectal cancer (CRC) and its related mechanisms through clinical samples from CRC patients, CRC cell lines and mouse models.

Improved Detection of Colibactin-Induced Mutations by Genotoxic E. coli in Organoids and Colorectal Cancer

[Cancer Cell] Co-culture of intestinal organoids with a colibactin-producing polyketide synthase E. coli strain revealed mutational signatures also found in colorectal cancer.

Inhibition of the AURKA/YAP1 Axis Is a Promising Therapeutic Option for Overcoming Cetuximab Resistance in Colorectal Cancer Stem Cells

[British Journal Of Cancer] The authors used transcriptomic analysis along with in vitro and in vivo models of RAS/RAF wild-type CRC to study YAP1 Ser397 phosphorylation as a potential biomarker for cetuximab resistance.

Targeting P2Y14R Protects against Necroptosis of Intestinal Epithelial Cells through PKA/CREB/RIPK1 Axis in Ulcerative Colitis

[Nature Communications] Based on the over-expression of P2Y14R in the intestinal epithelium of mice with experimental colitis, investigators reported that male mice lacking P2Y14R in intestinal epithelial cells exhibited less intestinal injury induced by dextran sulfate sodium.

Identification of EGR4 as a Prospective Target for Inhibiting Tumor Cell Proliferation and a Novel Biomarker in Colorectal Cancer

[Cancer Gene Therapy] The authors assessed the prognosis of colorectal cancer (CRC) based on early growth response 4 (EGR4) using the Kaplan-Meier plotter tool and tissue microarray.

Isoform Alterations in the Ubiquitination Machinery Impacting Gastrointestinal Malignancies

[Cell Death & Disease] The authors highlight reported examples of direct, protein-coded isoform variation of ubiquitination enzymes influencing cancer development and progression in gastrointestinal malignancies.

Preventing Early-Onset Colorectal Cancers Aim of $25 Million Award

[Washington University School of Medicine in St. Louis] Yin Cao, an associate professor at Washington University School of Medicine in St. Louis, is leading an international team seeking to understand what is driving the increase in early-onset colorectal cancers globally. Her team will do so with an award of up to $25 million over five years from Cancer Grand Challenges.

Synergistic Antitumor Activity between HER2 Antibody-Drug Conjugate and Chemotherapy for Treating Advanced Colorectal Cancer

[Cell Death & Disease] Researchers proposed the therapeutic efficacy and molecular mechanism underlying RC48, a FDA-approved anti human epidermal growth factor receptor 2 (HER2) antibody conjugate via a cleavable linker to the microtubule inhibitor monomethyl auristatin E, either alone or in combination with gemcitabine in various models of HER2-positive advanced colorectal cancer.

Since 2015, Intestinal Cell News has been a valuable resource for keeping researchers and medical professionals updated on the latest publications, news and events in the field of gastrointestinal cell biology. Our editorial team collects and publishes the most current articles and reviews using stomach, colon, and small and large intestinal cells. We cover topics including the culturing of intestinal cells, intestinal organoids, intestinal cancers, and gastrointestinal conditions such as irritable bowel syndrome and Crohn’s disease.

spot_img